Suven Pharmaceuticals Limited - Asset Resilience Ratio

Latest as of March 2025: 6.76%

Suven Pharmaceuticals Limited (SUVENPHAR) has an Asset Resilience Ratio of 6.76% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Suven Pharmaceuticals Limited (SUVENPHAR) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

Rs2.05 Billion
≈ $22.17 Million USD Cash + Short-term Investments

Total Assets

Rs30.32 Billion
≈ $327.87 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Suven Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. See what is Suven Pharmaceuticals Limited's book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Suven Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SUVENPHAR stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs2.05 Billion 6.76%
Total Liquid Assets Rs2.05 Billion 6.76%

Asset Resilience Insights

  • Limited Liquidity: Suven Pharmaceuticals Limited maintains only 6.76% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Suven Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio

Compare Suven Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 9.09%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.02%
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
Drug Manufacturers - Specialty & Generic 0.01%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%

Annual Asset Resilience Ratio for Suven Pharmaceuticals Limited (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Suven Pharmaceuticals Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 6.76% Rs2.05 Billion
≈ $22.17 Million
Rs30.32 Billion
≈ $327.87 Million
-27.57pp
2024-03-31 34.33% Rs7.74 Billion
≈ $83.69 Million
Rs22.54 Billion
≈ $243.77 Million
+12.84pp
2023-03-31 21.49% Rs4.22 Billion
≈ $45.68 Million
Rs19.66 Billion
≈ $212.59 Million
-4.81pp
2022-03-31 26.30% Rs4.81 Billion
≈ $52.04 Million
Rs18.30 Billion
≈ $197.86 Million
+14.05pp
2021-03-31 12.25% Rs1.81 Billion
≈ $19.53 Million
Rs14.74 Billion
≈ $159.46 Million
+9.63pp
2020-03-31 2.62% Rs306.76 Million
≈ $3.32 Million
Rs11.73 Billion
≈ $126.84 Million
+1.71pp
2019-03-31 0.90% Rs70.64 Million
≈ $763.92K
Rs7.83 Billion
≈ $84.68 Million
--
pp = percentage points

About Suven Pharmaceuticals Limited

NSE:SUVENPHAR India Drug Manufacturers - Specialty & Generic
Market Cap
$4.40 Billion
Rs406.97 Billion INR
Market Cap Rank
#3908 Global
#167 in India
Share Price
Rs1063.80
Change (1 day)
+4.50%
52-Week Range
Rs967.90 - Rs1149.00
All Time High
Rs1334.20
About

Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more